University of Cambridge Milner Logo  



Project Lead Namshik Han on the panel at Impact18 earlier this month, discussing how artificial intelligence is reshaping biotechnology and healthcare sectors. Read more »

Milner Update: July 2018


It is all hands on deck at The Milner Institute right now, as we ramp up and prepare to move in to our new building later this year!

We are delighted that the Milner team is growing and that Dr Rebecca Harris (Drug Discovery Programme Manager) and Marco Melfi (Scientific Facilities Coordinator) have joined us this month. Our Global Alliance Manager and Research Associate in machine-learning for drug discovery will join us in September.

One of our key aims is to connect and partner academics and companies in our consortium and global alliance. This month we've announced two ongoing case studies between Shionogi and world-leading academics in the Department of Physiology, Development and Neuroscience and the Department of Biochemistry at the University of Cambridge. Find out more about about these projects and the types of projects we enable here »

Our matchmaking activities have also been successful for Nemesis Bioscience and Shionogi, one of our Consortium partners. Nemesis Bioscience have just announced a £1.4m seed funding round which includes Shionogi Read more »

Our global alliance continues to grow and four new companies with novel capabilities, Fluidic Analytics, Pelago Bioscience, Cantabio and Enplas have joined us this month. You can read more about them in the Spotlight section below.

In addition to new memberships, our ongoing relationships with existing partners continue to thrive. At the end of June we held a joint symposium with Charles River Laboratories on collaboration, innovation and entrepreneurship in drug discovery. Packed with insight from academic and industry leaders including Prof Steve Jackson’s experience setting up Kudos and his newest company, Adrestia Therapeutics, Prof Rick Livesey’s candid opinion of the current challenges in developing new therapies for dementia and the latest developments in AI in drug discovery and development from Dr Ian Churcher, Benevolent AI. Charles River Laboratories also made a generous donation to charity for every participant who attended, a total of £2500 to CRUK.

P.S. Have you seen the Capella building exterior fly around video?! Check out the unique view here!


Register Now


Click here to register for the Milner Therapeutics Symposium 2018!

Register now for the third Milner Therapeutics Institute Symposium on 1st Oct 2018. This yearly networking event of 300+ scientists from biotech, pharma, CROs and academia is a fantastic opportunity to catalyse new partnerships and collaborations. The Symposium is a fantastic opportunity to showcase your research to our network of companies.

Please submit your abstracts to:


Affiliated Company Spotlight


Fluidic Analytics – Understand the Machinery of Life

Proteins are the building blocks of life. They form the structure of cells, regulate cellular activity and carry out the biochemical processes that underpin function in every living organism. Just as DNA tells us what could happen over lifetimes, proteins and their behaviour tell us what is happening now.

Fluidic Analytics envisions a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being.

By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit.

Fluidic Analytics are based in Cambridge and interested in talking to partners looking for novel tools to identify protein biomarkers, or who would like to explore new ways of optimising and monitoring protein purification, analysis and formulation.

To find out more about Fluidic Analytics, visit their website here »

Pelago Bioscience AB was founded in 2013 to develop and provide services based on the patented Cellular Thermal Shift Assay (CETSA). This assay is uniquely able to measure drug-target interactions in-situ within the cellular environment and can be applied against a specified protein target for compound screening and lead optimization (CETSA Classics and CETSA HT) or in a non-targeted proteomics study (CETSA Mass Spec). Critically CETSA require no modification to the ligand or target as it utilizes the natural thermodynamic properties of the protein itself and can be applied to any cell or sample type. CETSA MS is ideal for un-biased proteomics studies and is now used routinely for determining compound liabilities and for mode of action studies. A recent development has been the use of it to identify novel biomarkers. Pelago works exclusively on CETSA and is able to offer full assay development and screening services to its customers, using its own dedicated laboratories in Sweden.

To find out more about Pelago Bioscience AB, visit their website here »

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company, focusing on the research and development of disease modifying therapeutics candidates for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other related neurodegenerative diseases.

Through its proprietary drug discovery programs Cantabio is targeting the reduction of protein aggregation, oxidative and glyoxal stress, which are believed to be some of the main causes of AD and PD. Cantabio is currently developing small molecule pharmacological chaperones as drug candidates for clinical trials using an innovative therapeutic development approach. Cantabio focuses on three main protein targets and has four distinct therapeutic programs.

Cantabio’s strong management team has extensive experience in key strategic areas and has assembled a world-renowned scientific advisory board. The company has operations in Silicon Valley (USA), Cambridge (UK) and Budapest (Hungary), where multidisciplinary in-house R&D is carried out in our laboratory facility. Cantabio also has strong academic links with a number of academic institutions including the University of Cambridge and Purdue University, allowing cutting edge academic research support to Cantabio’s therapeutic programs.

To find out more about Cantabio Pharmaceuticals Inc, visit their website here »

At Cambridge Enplas Life science Lab (C.E.L.L), a subsidiary of Enplas Corporation, we are working on innovative research in the life science market.

Enplas decided to take a step forward in the life science market 17 years ago to answer the needs for microfluidic chips in the diagnostic market, by applying its core technology. With the creation of CELL, we are looking to apply this expertise to bring new innovations to the biotechnology market.

CELL as a lab is working on biotechnology applications such as organ on a chip, single cell, droplet microfluidics for the life science industry (pharmaceutical, cosmetic, food testing, environment). In addition, we are seeking new innovations where we can provide financial investment, management expertise, engineering support and global quality supply support. Enplas is also able to transform your ideas into a mass production chip using our expertise and global facilities.

To find out more about Enplas, visit their website here »


Affiliated Company News


Diagenode release new protocol to verify the efficiency and specificity of sgRNA in CRISPR experiments Read more »

Charles River Laboratories Expands Services for Early Discovery Screening Read more »

Charles River Laboratories announces Extended Relationship with The Michael J. Fox Foundation Read more »

Exonate shortlisted for UKBAA Best Investment in a High Growth Female Founder Award Read more »

Watch Exonate’s CEO Dr Catherine Beech feature in the Business Finance Guide video Read more »

Abcam and Shuwen Biotech sign strategic MoU to establish global alliance for companion diagnostic (CDx) kit development Read more »

Abcam/Merck collaboration produces new PD-L1 antibody for immuno-oncology research Read more »

Selcia announces that it has received renewal under the French Research Tax Credit scheme for the next 3 years. Read more »

BioAscent secures investment to expand its integrated drug discovery services Read more »

Linguamatics iScite 2.0 Wins Bio-IT World's Best of Show Judges' Prize Read more »

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs Read more »

Ubiquigent and Forma Therapeutics enter an exclusive R&D collaboration to develop novel DUB inhibitors Read more »

BioAscent form alliance with leading DMPK provider XenoGesis Read more »

Active Motif signs a Global Sales and Distribution Agreement with VolitionRx for its new RUO kits Read more »

Sphere Fluidics wins Red Herring 2018 Top 100 European Start Up Award Read more »

Agilent Technologies companion diagnostic gains expanded FDA approval in cervical cancer Read more »

CDC Foundation Program, supported by Amgen, to launch innovative tools to improve patient-provider conversations Read more »

PERT Consortium and BTG form strategic partnership to advance the science of Pulmonary Embolism (PE) treatment Read more »

MedAnnex Ltd receives SMART: SCOTLAND R&D Award Read more »


Funding Opportunities


WT Developing Concept Fund and MRC Confidence in Concept fund

Launch event: 20th July
Deadline for expressions of interest: 7th September

CATS and the Office of Translational Research invite University researcher-led applications for internal pump-priming funding for biomedical translational research. Read more »




Linguamatics Developer Open Evening
18th July 2018, Cambridge

Join the Linguamatics Solutions Development team to find out more about the cool technology and approaches they use to create their award winning software. An evening of pizza, drinks and presentations. Read more »

Knowing your audience, telling stories and why this matters
24th July 2018, Cambridge

This short interactive session from the Office of Postdoctoral Affairs (OPdA) is aimed at researchers looking to improve the effectiveness of their communication. It will introduce the importance of working out who your audience is and what they want to know. It will also explore how storytelling is as relevant to research communication as it is to fairy tales. We all have to communicate our research and ideas, why not do it through stories? Read more »

CRISPR Genome Editing: Design & Strategy
13th & 14th August 2018, Cambridge

Learn how to best implement techniques relating to this versatile and programmable sequence-specific endonuclease to expedite and enhance your research or product development. Read more »

International Congress on Epigenetics & Chromatin
3rd - 5th September 2018, London

International forum for cutting edge research in chromatin and epigenetics, providing “the focal hub” for people to present their research and exchange ideas. Read more »

CeBIL Annual Symposium: Precision Medicine, Artificial Intelligence and the Law
7th September 2018, Cambridge

This one-day symposium is the first annual symposium of CeBIL's 5 year project, bringing together researchers from across the world to investigate these and other issues on life science frontiers. It aims to tackle some of the challenging issues raised by black-box precision medicine, particularly for legal and regulatory frameworks. Read more »

Cambridge International Stem Cell Symposium
19th - 21st September 2018, Cambridge

This Symposium will bring together biological, clinical and physical stem cell scientists, working across multiple tissues and at different scales, to share data, discuss ideas and address the biggest fundamental and translational questions in stem cell biology. Read more »

Cambridge Immunology Forum
20th September 2018, Cambridge

This meeting will focus on the complex and fascinating area of “Cancer-Immunology”, covering aspects from basic science through to clinical application. We aim to bring together world leaders in Cancer immunology to provide a platform for scientific discussion, collaboration and the promotion of this exciting and developing field of research. Read more »

Data Challenges in Cardiovascular Research
24th September 2018, Cambridge

Registration is now open for this free event that aims to connect everyone in Cambridge with interest in data-related challenges. The main focus will be on cardiovascular research but the computational challenges and methods are applicable across healthcare and we welcome abstract submissions for short talks and posters outside cardiovascular field. Read more »

Crick Cancer Research Symposium
1st & 2nd October 2018, London

This meeting will provide early- and mid-career researchers with a platform for presenting their work, sharing ideas, and expanding their network. There will also be a sprinkling of talks from established leaders in cancer research, including René Bernards, Peter Friedl, Gerard Evan, and Kairbaan Hodivala-Dilke. Read more »

ELRIG Drug Discovery 2018
9th & 10th October 2018, London

This 2-day event will bring together more than 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel chemical and biological candidate drugs. Read more »




Director of Strategy (Immuno-oncology), Abcam. Read more »

Director of Strategy (Neuroscience), Abcam. Read more »

Research Area Lead (Epigenetics), Abcam. Read more »

Research Area Lead (Immuno-oncology), Abcam. Read more »

Senior Scientist (Innovation), Horizon Discovery. Read more »

Senior Scientist (Cell Culture), Modiquest. Read more »

Screening Scientist, PhoreMost. Read more »

Clinical Data Management Manager, Amgen. Read more »

Scientific Manager, Charles River Laboratories. Read more »

Medicinal Chemists & in vitro Bioscientists , BioAscent. Read more »

Medical Specialist, BTG. Read more »

Bioinformatics Scientist & More Jobs, Cambridge Epigenetics. Read more »

Software Engineer & More Jobs, Fluidic Analytics. Read more »

Senior Front-end Developer, Genestack. Read more »

Metabolomics Data Scientist, Healx Discovery. Read more »

Full Stack Developer, Intellegens. Read more »

Life Science Specialist, Linguamatics. Read more »

Software Engineers, Quid. Read more »

Bioinformatics Scientist, Repositive. Read more »

Contact us

The Milner Institute
University of Cambridge
Tennis Court Road
Cambridge CB2 1QN, UK
Tel: +44 (0)1223 767111 |

Subscribe | Unsubscribe